MRI Scanning for Pancreatic Cancer Detection

(DWI-PDAC Trial)

Overseen By Alexandre Brind'Amour, MD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Laval University

Disqualifiers: Locally advanced disease, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 1

40 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

Diffusion-weighted magnetic resonance imaging (DWI/MRI) has been described in recent literature as a highly sensitive and specific modality for the detection of peritoneal metastases (PM). It has been demonstrated to be superior to computed tomography (CT) for patients with known peritoneal disease from colorectal and gynaecological malignancies. However, the literature is scarce on the role of DWI/MRI in patients with pancreatic ductal-adenocarcinoma (PDAC). The aim of this study is to prospectively assess the added value of whole-body DWI/MRI (WB-DWI/MRI) to CT for detection of PM in the preoperative staging of patients with high-risk PDAC and evaluate how it correlates with intraoperative findings.

Who Is on the Research Team?

Alexandre Brind'Amour, MD

Principal Investigator

Laval University

Are You a Good Fit for This Trial?

This trial is for individuals with confirmed pancreatic ductal adenocarcinoma that can potentially be removed by surgery. They should have a tumor size of at least 3 cm and elevated CA 19-9 levels without distant metastases. Participants must be physically fit enough for pancreatic resection (ECOG performance status of 0 or 1).

Inclusion Criteria

My CA 19-9 levels are high, but my bilirubin is normal.

My tumor is larger than 3 cm.

My cancer has not spread to distant parts of my body.

Exclusion Criteria

You cannot have an MRI scan.

There is a suspicion that cancer has spread to other parts of the body, as seen on a CT scan.

I am not fit for pancreatic surgery due to my physical condition.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Imaging Assessment

Participants undergo whole-body DWI/MRI within 4 weeks of planned surgery to assess for peritoneal metastases

4 weeks

1 visit (in-person)

Surgical Evaluation

Participants with no evidence of PM on WB-DWI/MRI undergo pancreatic resection; those with suspicion of PM undergo diagnostic laparoscopy first

1-2 weeks

Follow-up

Participants are monitored for early distant recurrence and unexpected aborted surgery due to peritoneal metastases discovery

6 months

What Are the Treatments Tested in This Trial?

Interventions

• Whole-body diffusion-weighted magnetic resonance imaging

Trial Overview The study is testing the effectiveness of whole-body diffusion-weighted MRI in detecting peritoneal metastases in patients with high-risk pancreatic cancer, comparing its results to those from CT scans and correlating them with findings during surgery.

How Is the Trial Designed?

Group I: DWI-MRI Experimental Treatment 1 Intervention

Patients to undergo DWI-MRI (patients include in the study.

Who Is Running the Clinical Trial?

Laval University

Lead Sponsor

Trials

439

Recruited

178,000+